Stability‐indicating reversed‐phase‐HPLC method development and validation for sacubitril/valsartan complex in the presence of impurities and degradation products: Robustness by quality‐by‐design approach
Velusamy B. Subramanian, Naresh Kumar Katari, Vijetha Ponnam, Naresh Konduru, Thirupathi Dongala, Vishnu Murthy Marisetti, Govind Vyas
Abstract
Abstract According to current regulatory guidelines, a stability‐indicating method has been developed to determine the impurities in sacubitril (SCB) and valsartan (VLS) tablet dosage forms and perform robustness studies using the design of experiments approach. The present study was initiated to understand quality target product profile, analytical target profile, and risk assessment for method variables that affect the method response. A reversed‐phase‐HPLC system was equipped with a Phenomenex Gemini‐NX C 18 column (150 × 4.6 mm, 3 μm) and a photo diode array detector. A gradient mobile phase was used in this research work. The detection was performed at 254 nm; the flow rate was 1.5 mL/min, and the column temperature was maintained at 30°C. The proposed method was validated per the International Council for Harmonisation Q2 (R1) guidelines. The coefficient of correlation was >0.999 for all impurities. The limits of detection and quantification were evaluated for SCB, VLS, and all impurities. The precision and accuracy were obtained for SCB, VLS, and their related impurities. Intra‐ and inter‐day relative standard deviation values were less than 10.0%, and the recoveries of impurities varied between 90.0 and 115.0%. Based on the validation results, the proposed DoE method can estimate SCB and VLS impurities in the finished dosage form.